Morpholine, a strong contender for Fmoc removal in solid-phase peptide synthesis

被引:8
作者
Mthembu, Sinenhlanhla N. [1 ,2 ]
Chakraborty, Amit [1 ]
Schonleber, Ralph [3 ]
Albericio, Fernando [1 ,4 ,5 ,6 ]
de la Torre, Beatriz G. [1 ,2 ,6 ]
机构
[1] Univ KwaZulu Natal, Sch Chem & Phys, Peptide Sci Lab, Durban, South Africa
[2] Univ KwaZulu Natal, Coll Hlth Sci, Sch Lab Med & Med Sci, KwaZulu Natal Res Innovat & Sequencing Platform KR, Durban, South Africa
[3] Bachem AG, Bubendorf, Switzerland
[4] Univ Barcelona, Networking Ctr Bioengn Biomat & Nanomed, CIBER BBN, Barcelona, Spain
[5] Univ Barcelona, Dept Organ Chem, Barcelona, Spain
[6] Univ KwaZulu Natal, Sch Chem & Phys, Peptide Sci Lab, ZA-4000 Durban, South Africa
关键词
aspartimide; diketopiperazine; Fmoc; side reactions; solid-phase peptide synthesis; ASPARTIMIDE FORMATION; PROTECTING GROUP; SIDE REACTIONS; GLYCOPEPTIDE; SPPS; PREVENTION; PIPERIDINE; ACID;
D O I
10.1002/psc.3538
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Morpholine, which scores 7.5 in terms of greenness and is not a regulated substance, could be considered a strong contender for Fmoc removal in solid-phase peptide synthesis (SPPS). Morpholine in dimethylformamide (DMF) (50%-60%) efficiently removes Fmoc in SPPS, minimizes the formation of diketopiperazine, and almost avoids the aspartimide formation. As a proof of concept, somatostatin has been synthesized using 50% morpholine in DMF with the same purity as when using 20% piperidine-DMF.
引用
收藏
页数:11
相关论文
共 63 条
[1]   A backbone amide protecting group for overcoming difficult sequences and suppressing aspartimide formation [J].
Abdel-Aal, Abu-Baker M. ;
Papageorgiou, George ;
Raz, Richard ;
Quibell, Martin ;
Burlina, Fabienne ;
Offer, John .
JOURNAL OF PEPTIDE SCIENCE, 2016, 22 (05) :360-367
[2]   2022 FDA TIDES (Peptides and Oligonucleotides) Harvest [J].
Al Musaimi, Othman ;
Al Shaer, Danah ;
Albericio, Fernando ;
de la Torre, Beatriz G. .
PHARMACEUTICALS, 2023, 16 (03)
[3]   On-resin head-to-tail cyclization of cyclotetrapeptides: Optimization of crucial parameters [J].
Alcaro, MC ;
Sabatino, G ;
Uziel, J ;
Chelli, M ;
Ginanneschi, M ;
Rovero, P ;
Papini, AM .
JOURNAL OF PEPTIDE SCIENCE, 2004, 10 (04) :218-228
[4]  
Andersson L, 2000, BIOPOLYMERS, V55, P227, DOI 10.1002/1097-0282(2000)55:3<227::AID-BIP50>3.0.CO
[5]  
2-7
[6]  
[Anonymous], SCIFINDER CHEM ABSTR
[7]   Advances in Fmoc solid-phase peptide synthesis [J].
Behrendt, Raymond ;
White, Peter ;
Offer, John .
JOURNAL OF PEPTIDE SCIENCE, 2016, 22 (01) :4-27
[8]   From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future [J].
Bruckdorfer, T ;
Marder, O ;
Albericio, F .
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2004, 5 (01) :29-43
[9]  
Chan W., 1999, Fmoc solid phase peptide synthesis: a practical approach
[10]   The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules [J].
de la Torre, Beatriz G. G. ;
Albericio, Fernando .
MOLECULES, 2023, 28 (03)